Mounjaro vs Zepbound

Side-by-side comparison of Mounjaro and Zepbound — mechanism, indications, safety, trials, sponsor, and pricing.

At a glance

MounjaroZepbound
Generic nameMounjaroZepbound
SponsorNicholas SkertichThe University of Texas Medical Branch, Galveston
Molecular targetGastric inhibitory polypeptide receptor, Glucagon-like peptide 1 receptor—
ModalitySmall moleculeSmall molecule
PhaseFDA-approvedFDA-approved
Therapeutic areaMetabolicOther

Mechanism of action

Mounjaro—
Zepbound—

Approved indications

Mounjaro

  • Diabetes mellitus type 2

Zepbound

None tracked.

Common side effects

Mounjaro

  • Gastrointestinal adverse reactions (15 mg)
  • Gastrointestinal adverse reactions (10 mg)
  • Gastrointestinal adverse reactions (5 mg)
  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation

Zepbound

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Dyspepsia
  • Injection site reactions
  • Fatigue

Boxed warnings

Mounjaro

No boxed warnings.

Zepbound

  • WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. ZEPBOUND is contraindicated in patients wi

Further reading